Bordas-Martinez J, Vercher-Conejero J L, Rodriguez-González G, Notta P C, Martin Cabeza C, Cubero N, Lopez-Lisbona R M, Diez-Ferrer M, Tebé C, Santos S, Cortes-Romera M, Rosell A
Pulmonology Department, Hospital General de Granollers, Barcelona, Catalonia, Spain.
Pulmonology Department, Bellvitge Universitary Hospital, UB, IDIBELL, CIBERES, Barcelona, Catalonia, Spain.
Respir Res. 2025 Mar 24;26(1):113. doi: 10.1186/s12931-025-03121-z.
Mediastinal lymph node (LN) staging is routinely performed using PET/CT and EBUS-TBNA. Promising predictive algorithms for lymph nodes have been reported for each technique, both individually and in combination. This study aims to develop a predictive algorithm that combines EBUS, PET/CT and clinical data to provide a probability of malignancy.
A retrospective study was conducted on consecutive patients with non-small cell lung carcinoma staged using PET/CT and EBUS-TBNA. Lymph nodes were identified by level (N1, N2, and N3) and anatomical region (AR) (subcarinal, paratracheal, and hilar). A Standardized Uptake Value (SUV) was determined for each sampled LN. The ultrasound features collected included diameter in the short axis (DSA), morphology, border, echogenicity and the presence of the vascular hilum. A robust logistic regression model was used to construct an algorithm to estimate the probability of malignancy of the lymph node.
A total of 116 patients with a mean age of 66, 93% of whom were men, were included. 358 lymph nodes were evaluated, 51% of which exhibited adenocarcinoma and 35% were squamous, while 14% were classified as non-small-cell lung carcinoma. The model estimated the probability of malignancy for each lymph node using age, DSA, SUVmax, and AR. The Area Under the ROC curve, was 0.89. A user-friendly application was also developed ( https://ubidi.shinyapps.io/lymma/ .) CONCLUSIONS: The integration of patient clinical characteristics, EBUS features, and PET/CT findings may generate a pre-sampling malignancy probability map for each lymph node. The model requires prospective and external validation.
纵隔淋巴结(LN)分期通常采用PET/CT和超声支气管镜引导下经支气管针吸活检(EBUS-TBNA)进行。针对每种技术,无论是单独使用还是联合使用,都已报道了有前景的淋巴结预测算法。本研究旨在开发一种结合EBUS、PET/CT和临床数据的预测算法,以提供恶性肿瘤的概率。
对连续使用PET/CT和EBUS-TBNA进行分期的非小细胞肺癌患者进行回顾性研究。根据水平(N1、N2和N3)和解剖区域(AR)(隆突下、气管旁和肺门)识别淋巴结。为每个采样的淋巴结确定标准化摄取值(SUV)。收集的超声特征包括短轴直径(DSA)、形态、边界、回声性和血管蒂的存在情况。使用稳健的逻辑回归模型构建算法,以估计淋巴结恶性肿瘤的概率。
共纳入116例患者,平均年龄66岁,其中93%为男性。评估了358个淋巴结,其中51%表现为腺癌,35%为鳞癌,14%归类为非小细胞肺癌。该模型使用年龄、DSA、SUVmax和AR估计每个淋巴结的恶性概率。ROC曲线下面积为0.89。还开发了一个用户友好的应用程序(https://ubidi.shinyapps.io/lymma/ )。结论:整合患者临床特征、EBUS特征和PET/CT结果可为每个淋巴结生成采样前恶性概率图。该模型需要进行前瞻性和外部验证。